News

AL101, Ayala’s lead product candidate, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) and was granted Orphan Drug Designation in May 2019 for the treatment

Givlaari, an injection for subcutaneous use, is an RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) to treat AHP, an ultra-rare condition where patients experience severe abdominal

According to the company, Advil Dual Action with Acetaminophen is now the first OTC combination of ibuprofen and acetaminophen to get approval in the US. The new product

Financial considerations Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to

The divestment agreement was first announced in October 2019. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available

Forty Seven is engaged in the development of novel checkpoint therapies to stimulate macrophages for the treatment of cancer. The deal is expected to strengthen Gilead’s immuno-oncology research

In this connection, the FDA approved the company’s investigational new drug (IND) application for HBM4003. The biopharma company said that the US clinical study follows an initial trial

The Company’s primary focus will be on the development of CH5126766 (VS-6766), its RAF/MEK inhibitor, in combination with defactinib, its focal adhesion kinase (FAK) inhibitor, for the treatment

IXINITY® is an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by